Replies to post #185212 on Biotech Values

[biocqr]

CLDN > Is the statement below any cause for optimism?

Still, in what Zeiher called "the most important message of this pilot trial," there was evidence of a dose-response effect for two parameters that reflect ventricular remodeling—specifically, natriuretic peptide levels, which rose substantially less over six months in the SERCA2a groups than in the placebo group (they didn't rise at all in the high-dose group), and LV end-systolic volume, which rose sharply in the placebo group and declined in the high-dose SERCA2a group.

http://www.medscape.com/viewarticle/790633#vp_2

[WID]

Poorgrad, According to you, FDA panel might make a mistake to grant CLDN the Breakthrough Designation Therapy without looking at the info you presented?

I doubt that the company mislead the FDA on the CUPID1 data or the FDA shortsighted on the info you mentioned.

[xcernfsi]

Re: Celladon math

Thanks for this, PGS. Do you have a link to where "They note that they see anywhere from 20 to 365 copies of the AAV in a typical ug of DNA."?